Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACIP In Brief

Executive Summary

Merck Rotateq pricing: CDC estimates the cost-effective ceiling for a three-dose vaccination series of Merck's pending rotavirus vaccine is $67, the agency reported to its Advisory Committee on Immunization Practices Oct. 27. Merck has not set a price for the vaccine, but said it is committed to a level that will assure widespread use and availability. CDC predicts cost-effectiveness of a routine vaccination schedule for Rotateq would be in the same range as Sanofi-Aventis' meningococcal vaccine Menactra. ACIP's rotavirus vaccine working group is recommending universal administration of three doses of the vaccine at two, four and six months of age. Merck expects approval of Rotateq in early 2006. GlaxoSmithKline said it is in discussions with FDA about licensing its rotavirus vaccine Rotarix in the U.S...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel